This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
|
|
- Raymond Stevenson
- 5 years ago
- Views:
Transcription
1 abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is part f the clinical study reprt had been prepared in accrdance with best practice and applicable legal and regulatry requirements at the time f study cmpletin. The synpsis may include apprved and nn apprved uses, dses, frmulatins, treatment regimens and/r age grups; it has nt necessarily been submitted t regulatry authrities. A synpsis is nt intended t prvide a cmprehensive analysis f all data currently available regarding a particular drug. Mre current infrmatin regarding a drug is available in the apprved labeling infrmatin which may vary frm cuntry t cuntry.. Additinal infrmatin n this study and the drug cncerned may be prvided upn request based n Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis is supplied fr infrmatinal purpses nly in the interests f scientific disclsure. It must nt be used fr any cmmercial purpses and must nt be distributed, published, mdified, reused, psted in any way, r used fr any ther purpse withut the express written permissin.
2 Behringer Ingelheim Page: 1 f 6 Internatinal GmbH This is the Internatinal GmbH 16 Dec May 2003 Title f study: Investigatr: A Phase IV Safety Trial in Pediatric Patients (Ages 2-5) with Rhinrrhea Assciated with a Cmmn Cld r Allergy Multi-center study withut fficial designatin f a Principal f Crdinating Investigatr (See Sectin fr a cmplete list f investigatrs) Study center(s): 19 Publicatin (reference): Clinical phase: Objectives: Methdlgy: IIIb/IV T determine the safety f Nasal Spray 0.06% in pediatric patients (ages 2-5 years) with symptms f rhinrrhea assciated with a naturally ccuring cmmn cld, r frm symptms f rhinrrhea assciated with allergies. Multi-center, pen-label safety trial cnducted at 19 sites N. f patients enrlled: 268 Enrllment by trial grup: 45 in Cmmn Cld Grup; 223 in Allergy Grup ITT ppulatin: 230 N. f patient cmpleted: 214
3 Page: 2 f 6 This is the Diagnsis and main criteria fr inclusin: Cmmn Cld Ppulatin: Male r female at least 2 but nt lder than 5 years at screening; Diagnsis f a cmmn cld within 48 hurs f screening, with presence f swllen nasal membranes and/r presence f a fever; Capability f parent/legal guardian t administer trial drug and understand trial assessment questinnaire. Allergy Ppulatin: Male r female at least 2 but nt lder than 5 years at screening; Diagnsis f seasnal r perennial allergic rhinitis with a psitive skin r RAST test, psitive prir histry fr atpy and nasal symptms assciated with expsure t allergens; Capability f parent/legal guardian t administer trial drug and understand trial assessment questinnaire. Symptms assciated with rhinrrhea fr at least 48 hurs prir t the screening visit. Test prduct: Nasal Spray 0.06% dse: Thse with cmmn cld: tw sprays (84 mcg) per nstril t.i.d. mde f admin.: batch n.: Duratin f treatment: Thse with allergies: ne spray (42 mcg) per nstril t.i.d. Intranasal Spray Lt Numbers A (363 bttles expired May 2004) and A (10 bttles, expired June 2004) Thse with cmmn cld: 4 days Thse with allergies: 14 days Reference therapy: dse: mde f admin.: batch n.:
4 Page: 3 f 6 This is the Criteria fr evaluatin: Efficacy: Safety: Statistical methds: SUMMARY CONCLUSIONS: Primary efficacy variable: Patient s parent/legal guardian glbal assessment Secndary efficacy variable: Patient s parent/legal guardian daily assessment f symptms f rhinrrhea, nasal cngestin, and sneezing using a diary. Primary efficacy variable: adverse events Secndary efficacy variables: physican s nasal and tscpic examinatins and vital signs, physical examinatin and vital signs The primary endpint, the parent/legal guardian glbal assessment which determines the degree f symptm relief prvided by Nasal Spray 0.06%, was summarized and n statistical test was perfrmed. The secndary bjective f the trial was addressed by paired t-tests fr each f the rhinrrhea symptms (runny nse, nasal cngestin and sneezing). Fr each f the trial grups, cmparisns between the average f the daily Symptm Scres and baseline Symptm Scre were t be tested at the α=0.05 level fr the three rhinrrhea symptms. Fr this analysis, data frm all centers was cmbined. A ttal f 200 children, between the ages f 2 and 5, were t be enrlled in the trial. There were tw ppulatins: thse with rhinrrhea frm a cmmn cld (50 patients was the planned sample size, which was mdified t at least 30 patients in Amendment 2), and thse with rhinrrhea frm allergies (150 patients was the planned sample size, which was mdified t up t 170 patients in Amendment 2). This was a safety trial, and n frmal sample size calculatin was perfrmed.
5 Page: 4 f 6 This is the Efficacy results: This trial demnstrated that Nasal Spray 0.06% was useful, easy t use, and prvided relief fr runny nse in children 2.5 years f age with a cmmn cld r allergies. Sme imprvement was als seen in nasal cngestin and sneezing. Thirty-nine (39) f 43 parents/legal guardians f patients with a cmmn cld (91%) and 165 f 183 parents/legal guardians f patients with allergies (90%) fund Nasal Spray 0.06% either very useful r smewhat useful in treating yung children with a cmmn cld r allergies. Mrever 91% and 67% f parents/legal guardians, in the Allergy and Cmmn Cld Grups respectively, fund administratin f the nasal spray either extremely easy r very easy. Nasal Spray 0.06% shwed statistically significant imprvement in the symptm f runny nse in bth allergy and cmmn cld patients cnsistent with the knwn mechanism f an antichlinergic used in the treatment f rhinrrhea. Imprvement was als seen in nasal cngestin in bth trial grups. The change frm baseline in mean symptms scres, as assessed by the parents/legal guardians, was greatest fr runny nse in the Allergy and Cmmn Cld Grups (-1.0 and -1.6, respectively), fllwed by nasal cngestin (-0.7 and -0.8, respectively), and then sneezing (-0.2 and -0.6, respectively).
6 Safety results: Page: 5 f 6 This is the Overall, the use f Nasal Spray 0.06% was well tlerated in bth thse with a cmmn cld and thse with allergies. There were n deaths r serius adverse events in this trial and nly ne (0.5%) patient in the Cmmn Cld Grup and five (2.7%) patients in the Allergy Grup discntinued the trial because f an AE. Of these nly ne patient had an AE (epistaxis) that was cnsidered related t trial drug. There were 78 (33.9%) patients reprting a ttal f 142 AEs. Of these, 12 (27.9%) patients were in the Cmmn Cld Grup and 66 (35.3%) were in the Allergy Grup. The mst cmmn AEs reprted by the patients in the Cmmn Cld Grup were epistaxis, titis media, upper respiratry tract infectin, and fever. The mst cmmn AEs reprted by the patients in the Allergy Grup were fever, cughing, epistaxis, and titis media. There were n ptentially systemic antichlinergic adverse events reprted in either treatment grup. Nne f the AEs listed in these patients were cnsidered t represent previusly unsuspected r imprtant AEs if Nasal Spray 0.06%. Results f the nasal examinatins, perfrmed by the investigatrs, demnstrated that intranasal use f Nasal Spray 0.06% had n detrimental effect n the nasal mucsa. Indeed, imprvement was seen in mucsal clr, mucsal edema and rhinrrhea in bth trial grups. There was als n evidence that treatment with Nasal Spray 0.06% resulted in any apparent changes in vital sign evaluatins. Overall, Nasal Spray 0.06%, 84 mcg/nstril t.i.d. in children 2-5 years f age with cmmn clds, and 42 mcg/nstril t.i.d. in children 2-5 years f age with allergies was shwn t be safe.
7 Page: 6 f 6 This is the Cnclusins: Nasal Spray 0.06% was useful, easy t use, and prvided relief fr symptms f runny nse, stuffy nse, and sneezing in children 2-5 years f age with a cmmn cld r allergies. Nasal Spray 0.06% had n detrimental effect n nasal mucsa. The incidence f nasal adverse events was lw with six patients in the Cmmn Cld Grup and 11 patients in the Allergy Grup (ttal f 17 patients r 7.4%) reprting nasal AEs. The incidence f AEs leading t trial withdrawal was very lw with ne patient in the Cmmn Cld Grup and five patients in the Allergy Grup (ttal f six r 2.6%) discntinuing because f AEs. Nne f these AEs were cnsidered t represent previus unsuspected r imprtant Nasal Spray 0.06%. Nasal Spray 0.06% did nt cause any changes in vital signs.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationClinical Study Synopsis
Clinical Study Synpsis This Clinical Study Synpsis is prvided fr patients and healthcare prfessinals t increase the transparency f Bayer's clinical research. This dcument is nt intended t replace the advice
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationNCT ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: PRIST_L_ Study Code: PRISTINAMYCIN Date: Generic drug name:
These results are supplied fr infrmatinal purpses nly. Prescribing decisins shuld be made based n the apprved package insert in the cuntry f prescriptin Spnsr/cmpany: sanfi-aventis ClinialTrials.gv Identifier:
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More information2018 Medical Association Poster Symposium Guidelines
2018 Medical Assciatin Pster Sympsium Guidelines Overview The 3 rd Annual student-run Medical Assciatin f the State f Alabama Research Sympsium will take place n Friday and Saturday, April 13-14 at the
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationiprex Fact Sheet: Key Results
EMBARGOED UNTIL RELEASE Tuesday, 23 Nvember 2010, 8 a.m. EST CONTACT Mark Aurigemma; 646-270-9451; mark@aucmm.net Pedr Gicchea; 415-490-8350 pgicchea@gladstne.ucsf.edu iprex Fact Sheet: Key Results iprex
More informationSection 6 Students School District No. 71 (Comox Valley)
Sectin 6 Students Schl District N. 71 (Cmx Valley) Administrative Prcedure 6011 MR2 Allergies and Anaphylaxis 1. Intrductin The Bard f Educatin expects schls t reasnably accmmdate students with medically
More informationTriumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media
Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based
More informationAnnual Assembly Abstract Review Process
Annual Assembly Abstract Review Prcess AAHPM and HPNA cllabrate t review and select abstracts fr Annual Assembly. The cmmittees meet prir t the calls t review and update the Assembly bjectives (Planning
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More information2017 CMS Web Interface
CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...
More informationVaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE
Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More informationH1N1 Influenza 09 Guidance for Residential Aged Care
H1N1 Influenza 09 Guidance fr Residential Aged Care 11 June 2009 As knwledge abut H1N1 Influenza 09 develps, further advice will be prvided. Please check www.healthemergency.gv.au fr the latest infrmatin.
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.
Acute Immune Thrmbcytpenia Purpura (ITP) Backgrund Primary immune thrmbcytpenia (ITP) is an acquired immune mediated disrder characterised by islated thrmbcytpenia, defined as a peripheral bld platelet
More informationPET FORM Planning and Evaluation Tracking ( Assessment Period)
Divisin f: Behaviral Studies PET FORM Planning and Evaluatin Tracking (2010 2011 Assessment Perid) Persn Respnsible fr this Divisin: Jerry Mller Department f: Behaviral Sciences Persn Respnsible fr this
More informationTraining module 1: Summary
Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 1: Summary Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. The United States is currently experiencing a natinwide utbreak f entervirus D68 (EV-D68) assciated with severe
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. Over the last several mnths, the United States has experienced a natinwide utbreak f entervirus D68 (EV- D68) assciated
More informationEvidence Dossier to support COPD formulary decision making and guideline development
Evidence Dssier t supprt COPD frmulary decisin making and guideline develpment Prescribing and adverse event reprting infrmatin can be fund n the final pages f this dcument. Anr and Ellipta Trademarks
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationAnnex II. Scientific conclusions and grounds for. Variation to the terms of the Marketing Authorisations (oral formulations) and
Annex II Scientific cnclusins and grunds fr Variatin t the terms f the Marketing Authrisatins (ral frmulatins) and Revcatin f the Marketing Authrisatins (parenteral frmulatins) Scientific cnclusins Overall
More informationSection 5. Study Procedures
Sectin 5. Study Prcedures 5.1 Visit Lcatins... 1 5.2 Eligibility Determinatin... 1 5.3 Screening Visit... 2 5.3.1 Screening and Enrllment Timeframe... 2 5.3.2 Screening Visit Prcedures... 2 5.3.3 Screening
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More informationNovel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.
Nvel methds and appraches fr sensing, evaluating, mdulating and regulating md and emtinal states. 2018 Jy Academic Grant Call fr Prpsals Intrductin The Annual Jy grant initiative aims t prmte and cntribute
More informationAnnual Principal Investigator Worksheet About Local Context
Cmpleting the NCI CIRB Annual Principal Investigatr Wrksheet Abut Lcal Cntext and the Study-Specific Wrksheet Abut Lcal Cntext at the University f Iwa All investigatrs cnducting research with the Natinal
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationHuman papillomavirus (HPV) refers to a group of more than 150 related viruses.
HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between
More informationCDC Influenza Division Key Points November 7, 2014
In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationInfluenza (Flu) Fact Sheet
Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder
More informationImmunotherapy Guide Increases Dosing Accuracy. Jared Darveaux, MD
Immuntherapy Guide Increases Dsing Accuracy Jared Darveaux, MD Disclsures Nne ON TARGET Backgrund Immuntherapy (IT) is a therapeutic tl used t treat allergic rhinitis and allergic asthma fr decades In
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationMEDICATION GUIDE. Reference ID:
MEDICATION GUIDE GLYXAMBI (glik-sam-bee) (empagliflzin and linagliptin) Tablets Read this Medicatin Guide carefully befre yu start taking GLYXAMBI and each time yu get a refill. There may be new infrmatin.
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationSUICIDE AND MENTAL ILLNESS IN SINGAPORE
Vl. 15, N. 3. SINGAPORE MEDICAL JOURNAL 191 September, 1974. SUICIDE AND MENTAL ILLNESS IN SINGAPORE By W. F. Tsi and B. H. Chia SYNOPSIS This is a study f 112 cases f suicides wh had a past histry f being
More informationMANITOBA HEALTH, HEALTHY LIVING & SENIORS WEEKLY WEST NILE VIRUS SURVEILLANCE REPORT (WEEK 27)
MANITOBA HEALTH, HEALTHY LIVING & SENIORS WEEKLY WEST NILE VIRUS SURVEILLANCE REPORT (WEEK 27) The weekly West Nile Virus Surveillance Reprt utlines the mst current surveillance data and is psted weekly
More informationChapter 6: Impact Indicators
Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the
More informationEXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS
1 SECTION 1 INTRODUCTION: EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS The Nature Of Assessment The Definitin Of Assessment The Difference Between Testing, Measurement And Evaluatin Characteristics
More informationTable of Contents (Click on title to jump to section)
Table f Cntents (Click n title t jump t sectin) Overviews: Pre-pubertal (tanner 1,2) Assault Quick Guide Pst-pubertal (tanner 3,4,5) Assault Quick Guide Sectins: Pre-pubertal 1) Acute Assault 2) Sub-acute
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationLyme Disease Surveillance in North Carolina
Lyme Disease Surveillance in Nrth Carlina 2008-2014 Carl Williams DVM Megan Sanza MPH Cmmunicable Disease Branch Divisin f Nrth Carlina Public Health Lyme Disease Surveillance in Nrth Carlina 2008-2014
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationStudy Design Open, three arm-stratified, non-randomized, prospective, multicentric study
PONS Study Synpsis Title f the Study Subtype-Stratified Fllw-up Care Study f Breast Cancer Patients with Cmbined In Vitr and In Viv Diagnstics Plus Early Target-Oriented Interventin Gals Imprve and individualize
More informationAnnex E Terms of Reference: Therapeutic use
Annex E Terms f Reference: Therapeutic use The purpse f the pre-review reprt is t synthesize existing scientific evidence abut the therapeutic use and ptential fr dependence and abuse f cannabisrelated
More informationDATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS
DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this
More informationA fake medicine that passes itself off as a real, authorised medicine. (1)
Falsified medicines Index 1 Intrductin 2 Types f falsified medicines 3 Eurpean regulatin n falsified medicines 4 Risks f falsified medicines 5 Buying medicine nline safely 6 References 7 Further resurces
More informationSCALES NW HEARING PROTECTION PROGRAM
PURPOSE Expsure t excessive nise in the wrkplace can cause permanent hearing lss. The Hearing Prtectin Prgram has been established t help ensure that emplyees f Scales NW, Inc. d nt suffer health effects
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationRecommendations for Risk Management at Swine Exhibitions and for Show Pigs August 2012
Recmmendatins fr Risk Management at Swine Exhibitins and fr Shw Pigs August 2012 Backgrund: The Natinal Prk Bard facilitated in develping this dcument. These recmmendatins were develped by a wrking grup
More informationEXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION
EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationGuideline Number: NIA_CG_301 Last Revised Date: October 2014 Responsible Department: Implementation Date: October 2014 Clinical Operations
Natinal Imaging Assciates, Inc. Clinical guidelines PARAVERTEBRAL FACET JOINT INJECTIONS OR BLOCKS CPT Cdes: Cervical Thracic Regin: 64490 (+ 64491, +64492), 0213T (+0214T, +0215T) Lumbar Sacral Regin:
More informationHigh Performance Network Quality Criteria for Designation
Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain
More informationReliability and Validity Plan 2017
Reliability and Validity Plan 2017 Frm CAEP The principles fr measures used in the CAEP accreditatin prcess include: (a) validity and reliability, (b) relevance, (c) verifiability, (d) representativeness,
More informationProstatitis - chronic - Management
Prstatitis - chrnic - Management Scenari: Diagnsis f chrnic prstatitis Hw shuld I diagnse chrnic prstatitis? Diagnse chrnic prstatitis if: The man has pain in the perineum r pelvic flr and lwer urinary
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationHearing Conservation Program
Hearing Cnservatin Prgram FOREWORD Nise-induced hearing lss (NIHL) is a permanent and irreversible ccupatinal illness due t expsure t excessive nise. The Occupatinal Safety and Health Administratin (OSHA)
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0444 TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION:
More informationApril 23, 2008 Information Sheet: Safety of BPA-derived Can Liners. Summary
April 23, 2008 Infrmatin Sheet: Safety f BPA-derived Can Liners Summary The use f bisphenl A (BPA)-derived epxy resins t make prtective catings fr metal fd and beverage packaging helps prvide safe, whlesme
More informationOTHER AND UNSPECIFIED DISORDERS
OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationJefferies 2014 Global Healthcare Conference. June 3, 2014
Jefferies 2014 Glbal Healthcare Cnference June 3, 2014 Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s financial results, business prspects and
More informationSPINRAZA (NUSINERSEN)
SPINRAZA (NUSINERSEN) UnitedHealthcare Oxfrd Clinical Plicy Plicy Number: PHARMACY 295.4 T2 Effective Date: April 1, 2018 Table f Cntents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE... 1 BENEFIT
More information2018 CMS Web Interface
CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.0 Page 1 f 27 11/13/2017 Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...
More informationInfection Control Guidelines for Cabin Crew Members on Commercial Aircraft
Infectin Cntrl Guidelines fr Cabin Crew Members n Cmmercial Aircraft PURPOSE These guidelines prvide cabin crew members (flight attendants) with practical measures t prtect themselves, passengers, and
More informationOriginal Policy Date 12:2013
MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our
More informationPodcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10
Pdcast Transcript Title: Cmmn Miscding f LARC Services Impacting Revenue Speaker Name: Ann Finn Duratin: 00:16:10 NCTCFP: Welcme t this pdcast spnsred by the Natinal Clinical Training Center fr Family
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationFTD RESEARCH: The Value of Studies and Opportunities for Involvement
FTD RESEARCH: The Value f Studies and Opprtunities fr Invlvement Sarah Lawrence, MS Research Prgram Manager Ann Fishman, MBA Sr. Research Crdinatr Weiyi Mu, ScM Genetic Cunselr Suzanne Dana Spuse/Caregiver
More informationAppendix C. Master of Public Health. Practicum Guidelines
Appendix C Master f Public Health Practicum Guidelines 0 Gergia State University, Schl f Public Health Master f Public Health Practicum Guidelines Fr mre infrmatin, cntact Jessica Hwell Pratt, MPH Practicum
More information2017 CMS Web Interface
CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF 0055): Diabetes: Eye Exam Measure Steward: NCQA Web Interface
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationMedical Student Immunization Requirements
Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationWCPT awards programme 2015
WCPT awards prgramme 2015 The WCPT awards prgramme recgnises utstanding cntributins and leadership by individual physical therapists and grups t the prfessin and/r glbal health at an internatinal level.
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More informationMEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion
MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new
More informationPhysical Fitness for the Physically Limited. o Work Experience, General. o Open Entry/Exit. Distance (Hybrid Online) for online supported courses
SECTION A - Curse Infrmatin 1. Curse ID: 2. Curse Title: 3. Divisin: 4. Department: 5. Subject: 6. Shrt Curse Title: 7. Effective Term:: KINL 2 Physical Fitness fr the Physically Limited Kinesilgy & Athletics
More informationPROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS
PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards
More informationAPA-accredited: YES NO X. Brown University. Stephen Salloway, M.D. (Primary Supervisor) Paul Malloy, Ph.D.
Clinical Psychlgy Training Prgrams at Brwn: A Cnsrtium f the Prvidence VA Medical Center, Lifespan, and Care New England Pstdctral Fellwship Training Prgram Pstdctral Fellwship Descriptin: RESEARCH FOCUS
More informationImmunisation and Disease Prevention Policy
Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries
More informationCommonwealth of Kentucky Department for Medicaid Services Division of Program Quality and Outcomes
Cmmnwealth f Kentucky Department fr Medicaid Services Divisin f Prgram Quality and Outcmes EPSDT Screening Encunter Data Validatin Clinical Fcused Study 2014 FINAL REPORT May 2014 TABLE OF CONTENTS INTRODUCTION...
More informationVaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE
Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationFlu Season Key Points ( )
2014-2015 Flu Seasn Key Pints (10-31-14) Cntents Overarching Framewrk f CDC Influenza Messaging... 3 Take 3 Messages... 3 Statements fr General Audiences... 4 Disease... 4 Vaccinatin... 6 Vaccinatin Timing...
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationNeurological outcome from conservative or surgical treatment of cervical spinal cord injured patients
1993 nternatinal Medical Sciety f Paraplegia eurlgical utcme frm cnservative r surgical treatment f cervical spinal crd injured patients J E Kiwerski Spinal Department f Metrplitan Rehabilitatin Centre,
More informationLittle Angels Schoolhouse
Little Angels Schlhuse Sickness and Illness Plicy Aim Early Years Fundatin Stage Statutry Guidance The Prvider must prmte the gd health f the children, take necessary steps t prevent the spread f infectin
More informationAUTHORISED BY: CEO. Introduction. Whistle Blowing
GUIDELINE NAME: Field Cmplaints Disclsure Guidelines SECTION : Refer t Excel Guidelines list Dcument N: DISTRIBUTION: All Emplyees FIRST ISSUED: April 2013 DATE UPDATED: Dec 2014 ISSUED/UPDATED BY: Peple
More information